BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fuggle NR, Curtis B, Clynes M, Zhang J, Ward K, Javaid MK, Harvey NC, Dennison E, Cooper C. The treatment gap: The missed opportunities for osteoporosis therapy. Bone 2021;144:115833. [PMID: 33359889 DOI: 10.1016/j.bone.2020.115833] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Kanis JA, Mccloskey EV, Harvey NC, Cooper C, Rizzoli R, Dawson-hughes B, Maggi S, Reginster J. The need to distinguish intervention thresholds and diagnostic thresholds in the management of osteoporosis. Osteoporos Int 2022. [DOI: 10.1007/s00198-022-06567-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Geusens P, Appelman-Dijkstra NM, Zillikens C, Willems H, Lems WF, van den Bergh J. How to implement guidelines and models of care. Best Pract Res Clin Rheumatol 2022;:101759. [PMID: 35729036 DOI: 10.1016/j.berh.2022.101759] [Reference Citation Analysis]
3 Zhao J, Lin F, Liang G, Han Y, Xu N, Pan J, Luo M, Yang W, Zeng L. Exploration of the Molecular Mechanism of Polygonati Rhizoma in the Treatment of Osteoporosis Based on Network Pharmacology and Molecular Docking. Front Endocrinol (Lausanne) 2021;12:815891. [PMID: 35069454 DOI: 10.3389/fendo.2021.815891] [Reference Citation Analysis]
4 Debiais F. Ostéoporose masculine : des recommandations pour améliorer sa prise en charge. Revue du Rhumatisme 2022;89:113-115. [DOI: 10.1016/j.rhum.2021.05.009] [Reference Citation Analysis]
5 McArthur C, Lee A, Alrob HA, Adachi JD, Giangregorio L, Griffith LE, Morin S, Thabane L, Ioannidis G, Lee J, Leslie WD, Papaioannou A. An update of the prevalence of osteoporosis, fracture risk factors, and medication use among community-dwelling older adults: results from the Canadian Longitudinal Study on Aging (CLSA). Arch Osteoporos 2022;17:31. [PMID: 35122160 DOI: 10.1007/s11657-022-01073-1] [Reference Citation Analysis]
6 Montoya-Garcia MJ, Carbonell-Abella C, Cancio-Trujillo JM, Moro-Álvarez MJ, Mora-Fernández J, Izquierdo-Avino R, Nogues X, Mesa-Ramos M, San Segundo-Mozo RM, Calero-Muñoz E, Naves-Diaz M, Olmo-Montes FJ, Duaso E; GRUPO REFRA-FLS. Spanish National Registry of Major Osteoporotic Fractures (REFRA) seen at Fracture Liaison Services (FLS): objectives and quality standards. Arch Osteoporos 2022;17:138. [PMID: 36318373 DOI: 10.1007/s11657-022-01174-x] [Reference Citation Analysis]
7 Debiais F. Male osteoporosis: Recommendations to improve its treatment. Joint Bone Spine 2021;88:105250. [PMID: 34274519 DOI: 10.1016/j.jbspin.2021.105250] [Reference Citation Analysis]
8 Soen S, Kaku M, Okubo N, Touzeni S, Saito K, Kobayashi M. Epidemiology of glucocorticoid-induced osteoporosis and management of associated fracture risk in Japan. J Bone Miner Metab 2021. [PMID: 34125296 DOI: 10.1007/s00774-021-01236-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]